Market Segmentation:
- By Infection Type
- Complicated Pyelonephritis
- Complicated Lower UTI
- Catheter-associated UTI
- Others (Urologic Procedure-associated UTI, Renal Transplant-associated UTI)
- By Pathogen Type
- Escherichia coli
- Klebsiella pneumoniae
- Pseudomonas aeruginosa
- Enterobacter spp.
- Proteus spp.
- Acinetobacter baumannii
- Others (Enterococcus spp., Staphylococcus spp.)
- By Drug Class
- Aminoglycosides
- Cephalosporins
- Carbapenems
- Fluoroquinolones
- Others (Polymyxins, Tetracyclines)
- By Route of Administration
- Intravenous
- Oral
- Others (Intramuscular, Topical)
- By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Others (Clinics, Medical Stores)
- By End User
- Hospitals
- Clinics
- Ambulatory Surgical Centers
- Others (Long-term Care Facilities, Home Healthcare)
- By Regions
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Frequently Asked Questions
The current market size of the Complicated Urinary Tract Infections industry is USD 2.8 billion.
Rising antimicrobial resistance, increasing hospital-acquired infections, aging population susceptible, inadequate antibiotic development, rising prevalence of chronic diseases, advancements in diagnostic tools, growing demand for effective treatments, increasing healthcare expenditure, and technological innovations.
Stringent regulatory approvals, high treatment costs, limited R&D funding, off-label antibiotic use, lack of awareness, and patent expirations of existing drugs.
The catheter-associated UTI segment is the leading component segment in the Complicated Urinary Tract Infections Market due to the increasing use of indwelling catheters.
Merck & Co., Pfizer Inc., GlaxoSmithKline plc, Novartis AG, Bayer AG, Allergan plc, Melinta Therapeutics, Achaogen, Inc., Tetraphase Pharmaceuticals, and Iterum Therapeutics plc.
The North America region is expected to lead the Complicated Urinary Tract Infections Market with a market share of 38.2% in 2023.
Rising antimicrobial resistance, increasing hospital-acquired infections, aging population, inadequate antibiotic development, rising prevalence of chronic diseases, advancements in diagnostic tools, growing demand for effective treatments, and technological innovations.